SCHEDULE 13G/A: BlackRock Discloses 8.3% Stake in Celldex Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.3% in Celldex Therapeutics, Inc. as of December 31, 2024.

Summary

• BlackRock, Inc. reported beneficial ownership of 5,480,670 shares of Celldex Therapeutics, Inc. common stock.
• This represents 8.3% of the total outstanding common stock of Celldex Therapeutics, Inc.
• BlackRock holds sole voting power over 5,332,298 shares and sole dispositive power over 5,480,670 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Various BlackRock subsidiaries, including BlackRock Life Limited, BlackRock Advisors, LLC, and BlackRock Institutional Trust Company, National Association, are involved in the beneficial ownership, with some entities beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by a major institutional investor like BlackRock is generally viewed as a neutral to slightly positive signal, indicating confidence in the company without implying active management intervention.

Positives

• BlackRock, Inc., a prominent institutional investor, has disclosed a significant 8.3% beneficial ownership stake in Celldex Therapeutics, Inc., which can be interpreted as a vote of confidence in the company's prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a major institutional investor like BlackRock may instill confidence and potentially attract further institutional investment, positively impacting shareholder perception.

Key Dates

Keywords

Celldex Therapeutics, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals